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ApoptosisMicroglia contributes signiﬁcantly to brain tumor mass, particularly in astrocytic gliomas. Here, we examine
the cytotoxic effects of soluble components secreted from microglia culture on glioma cells. Microglia
conditioned culture medium (MCM) actively stimulated apoptotic death of glioma cells, and the effects of
MCM prepared from LPS- or IFN-γ-activated microglia were more pronounced. The cytotoxic effects were
glioma-speciﬁc in that primary cultured rat astrocytes were not affected by MCM. A donor of peroxynitrite
induced glioma-speciﬁc cell death. In addition, NO synthase inhibitor suppressed glioma cell death induced
by activated MCM, indicating that NO is one of the key molecules responsible for glioma cytotoxicity
mediated by activated MCM. However, since unstimulated resting microglia produces low or very limited
level of NO, MCM may contain other critical molecule(s) that induce glioma apoptosis. To identify the
proteins secreted in MCM, proteomic analysis was performed on control or activated medium. Among over
200 protein spots detected by Coomassie blue staining, we identiﬁed 26 constitutive and 28 LPS- or IFN-γ-
regulated MCM proteins. Several cathepsin proteases were markedly expressed, which were reduced upon
activation. In particular, suppression of cathepsin B by the chemical inhibitors signiﬁcantly reversed MCM-
induced glioma cell death, implying a critical role of this protease in cytotoxicity. Our ﬁndings provide
evidence on the functional implications of speciﬁc microglial-secreted proteins in glioma cytotoxicity, as well
as a basis to develop a proteomic databank of both basal and activation-related proteins in microglia.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Malignant gliomas are among the most fatal cancer types. In
addition to neoplastic cells, the tumor microenvironment comprises
nonmalignant cells, such as lymphocytes, astrocytes, endothelial cells,
microglia, and macrophages, which inﬂuence cancer growth and
therapeutic efﬁcacy. Signiﬁcant macrophage andmicroglia inﬁltration
in both human and animal brain tumors has been consistently
reported [1–4], and there is compelling evidence that microglia play
an active role in glioma development [2,5]. However, the involvement
of microglia in controlling the growth and inﬁltration of tumor cells
remains a topic of controversy. Microglial cells are present in both the
necrotic areas of brain tumor and intact tumor tissue of astrocytic
gliomas, supporting a potential role in tumor promotion [6]. On the
other hand, microglial secretory compounds may inhibit glioma
development via suppression of glioma cell growth [7]. In this case,
the biological success of glioma indicates that natural microglial+82 32 890 0647.
ll rights reserved.defense mechanisms do not function properly. For example, glioma-
inﬁltrating microglia's anti-tumor activity is limited by characteristic
down-regulation of microglial peripheral benzodiazepine receptor.
Microglial activity possibly depends on the type of tumor, immune
status, or interactions with other cells in the brain.
Peroxynitrite, a highly reactive molecule formed by the near-
diffusion reaction of nitric oxide (NO) and superoxide anion, is one of
the most potent neurotoxic agents targeting both neurons and glial
cells [8,9]. While astrocytes are relatively more resistant to oxidative
injury than neurons due to the high level of intracellular oxidants,
including glutathione [10], several investigators report that peroxy-
nitrite exerts cytotoxic effects on astrocytes at submillimolar concen-
trations in cultured cells [11–13]. In contrast, several conﬂicting studies
show that peroxynitrite displays cytoprotective effects depending on
its concentration, cell type, and the oxidative states [14–16].
Proteomic analysis is one the most powerful methods for the
identiﬁcation of secretory proteins [17,18]. In the present study, we
employed the proteomic approach to obtain an unbiased overview of
the proteins secreted bymicroglia cultures. Notably, cathepsin proteins
are abundant in the supernatant fractions of microglia culture.
Accumulating evidence shows that intracellular and extracellular
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nervous system (CNS) through both nonspeciﬁc and limited proteo-
lysis. Cathepsin B speciﬁcally exerts cytotoxic effects in the CNS.
Microglia-secreted cathepsin B plays an important role in Aβ-induced
neuronal apoptosis [19].Moreover, in slice cultures from rodents and in
vivo studies on primates, selective cathepsin B inhibitors protect
against ischemia-induced neuronal damage [20], which is partly
mediated by inﬂammatory and immunological reactions [21].
Here, we show that microglia induce apoptosis of glioma cells via
the release of NO and cathepsin B protease. Our ﬁndings collectively
indicate that the initiation or development of gliomas may be
constitutively monitored by neighboring microglia cells via release
of these factors, and breakdown of this balance is associated with
tumor progression. Thus, effective regulation of microglia recruitment
or activation may contribute to the successful therapeutic targeting of
brain neoplasms.
2. Materials and methods
2.1. Reagents
Bacterial lipopolysaccharide (LPS), thrombin, propidium iodide (PI),
4′6-diamidino-2-phenylindole (DAPI), 3-morpholinosydnonimine
(SIN-1), NG-monomethyl-l-arginine (l-MMNA), 4-(2-aminoethyl)
benzenesulfonylﬂuoride (AEBSF), trans-epoxysuccinyl-leucylamido
(4-guanidino)butane (E-64), pepstatin, N-acetyl-L-leucyl-L-leucyl-L-
norleucinal (LLnL), and cathepsin B were purchased from Sigma
Chemical Company. CA-074me (Calbiochem) and Z-Val-Ala-Asp-FMK
(zVAD-fmk) (Enzyme Systems Products) were obtained from local
suppliers.
2.2. Cell cultures
The murine BV2 cell line has been used as a suitable model for in
vitro studies of activated microglial cells [22]. It has been veriﬁed that
the behavior of the BV2 microglial cell line closely mimics that of
microglia cells in primary culture [22,23]. BV2 cells were maintained
at 37 °C at 5% CO2 in Dulbecco's modiﬁed Eagle's medium (DMEM)
supplemented with 10% heat-inactivated endotoxin-free fetal bovine
serum (FBS) (Hyclone), 2 mM glutamine, 100 μg/ml streptomycin,
and 100 U/ml penicillin. U373-MG and U87-MG human glioma [24]
and C6 rat glioma cell lines were cultured in DMEMmedium and CRT-
MG human glioma cells [25] were cultured in RPMI-1640 medium,
each supplemented with 10% FBS, streptomycin, and penicillin.
2.3. Preparation of primary astrocytes and microglia
Primary microglia were prepared from 1-day-old Sprague Dawley
rats as described previously, with some modiﬁcations [22]. In brief,
animals were sacriﬁced by decapitation, the cerebral cortex was
aseptically isolated, and the meninges were carefully removed. The
tissue was dissociated in 0.25% trypsin in PBS. Cells were triturated
into single cells in MEM containing 10% FBS, and plated on MEM
supplemented with 2 mM L-glutamine, 33 mM glucose, 3 mM
NaHCO3, 10 mM HEPES, and 10% FBS for 10–14 days. To prepare
microglia, cells were removed from the T75-ﬂasks by mild shaking at
200 rpm for 2 h [26]. Enriched microglia were nearly pure (N95%), as
evident from immunocytochemical staining for a microglia-speciﬁc
marker, the CR3 complement receptor, detected using the OX-42
antibody (Roche Diagnostics). Astrocytes remaining in T75 ﬂasks after
removal of microglia were harvested with 0.1% trypsin. Astrocytes
were subcultured twice to ensure sufﬁcient purity for experiments.
Astrocyte purity was conﬁrmed by staining for speciﬁc glial ﬁbrillary
acidic protein (GFAP) (usually N99%). All experiments were carried
out in accordance with “The Guidelines for Animal Research at Inha
University School of Medicine”.2.4. Preparation of microglia conditioned culture medium
For conditioned medium transfer, primary cultured rat or BV2
mouse microglial cells were plated and either left untreated or
stimulated with LPS, IFN-γ, or thrombin. Cell-free supernatant
fractions were collected after 24–72 h of treatment, and applied to
primary astrocytes or various glioma cell lines.
MCM for proteomic analysis was prepared as follows: cells were
grown at 1.2×107/cells/140 cm2, washed three times with PBS, and
cultured in serum-free medium containing either LPS or IFN-γ. After
24 h, conditioned culture mediumwas collected by centrifugation, and
passed through a 0.2 μmporemembraneﬁlter (Millipore).Mediumwas
concentrated with a centrifugal concentrator (Centriprep P-10; Milli-
pore), andprecipitatedwith10% (v/v) TCA for 4 h at 4 °C. The pelletwas
washed with ethanol, and resuspended in urea buffer (7 M urea, 2 M
thiourea, 40 mM Tris, 4% CHAPS, 0.5% carrier [Resolyte pH 3.5–10]
ampholytes, 15mMDTT, 1mMEDTA, 1mMPMSF, 2%protease inhibitor
cocktail, 0.008% bromophenol blue) for 2-D (0.4 mg/gel) gel analysis.
2.5. Cell viability
Cells were grown in 24-well plates at a concentration of 5×104
cells/2 cm2 followed by proper treatment. Morphological change
was examined under the upright type phase-contrast microscopy
(Olympus). Fifty microliters of 5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrasolium bromide (MTT) (Sigma-Aldrich) in growth
mediumwere added to eachwell. After incubation for 4 h at 37 °Cwith
MTT, cell mediumwas removed. The precipitated formazan, a product
of MTT tetrazolium ring by the action of mitochondrial dehydro-
genases, was solubilized with dimethyl sulfoxide and quantiﬁed
spectrophotometrically at 540 nm.
2.6. Nitrite assay
NO production was determined by measuring the amount of
nitrite, a relatively stable oxidation product of NO, as described
previously [22]. In brief, an aliquot of the conditioned culture medium
was mixed with an equal volume of 1% sulfanilamide in water and
0.1% N-1-naphthylethylenediamine dihydrochloride in 5% phosphoric
acid. The absorbance was determined at 540 nm. Sodium nitrite was
used to generate a standard curve.
2.7. Apoptosis assay by DAPI staining
DAPI staining was performed as reported previously [26], with
some modiﬁcations. In brief, attached cells were washed with PBS,
and ﬁxed with 4% PBS-buffered paraformaldehyde solution for 30 min
at RT. Fixing solution was removed, and cells were washed with PBS.
Cells were treated with pure 0.5% Triton X-100 in PBS, and incubated
for 15 min. Next, cells were rinsed with PBS for 5 min, and stained
with 1 μg/ml DAPI in the dark for 30 min. Following rinsing with PBS
and mounting on glass slides, at least 300 cells per condition were
subjected to examination using a ﬂuorescence photomicroscope (Carl
Zeiss). Apoptotic cells were identiﬁed on the basis of morphology, as
well as condensation and fragmentation of nuclei.
2.8. Flow cytometric analysis of the cell cycle
Cell cycle analysis was performed as reported previously [27], with
some modiﬁcations. For cell cycle analysis, 1×106 BV2 cells were
washed twice with PBS. Cells were ﬁxed with 70% ethanol at−20 °C
for at least 12 h. After two washes with PBS, cells were incubated in
RNase A/PBS (100 μg/ml) at 37 °C for 30 min. Intracellular DNA was
labeled with PI (50 μg/ml) for 30 min on ice protected from light, and
analyzed with a FACSCalibur ﬂuorescence-activated cell sorter (FACS)
(Becton Dickinson).
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Prepared cells were resuspended in lysis buffer (10 mM Tris,
140 mM NaCl, 1% Triton, 0.5% SDS, and protease inhibitors, pH 8.0)
and cleared from cellular debris by centrifugation. Protein samples
(20 μg for regular Western and 40 μg for 2-D Western blotting) were
separated by SDS–PAGE and transferred to Hybond™-ECL™ mem-
brane (Amersham Biosciences). The membrane was blocked with 5%
BSA in TBST solution (10 mM Tris–HCl, pH 8.0, containing 150 mM
NaCl and 0.5% Tween 20). Blots were incubated with human PARP (BD
Pharmingen), iNOS (BD Pharmingen), apolipoprotein E (Santa Cruz
Biotechnology), cathepsin A (R&D Systems), cathepsin B (Abcam),
cathepsin D (Abcam), cathepsin L (R&D Systems), or HSP60 (Abcam).
Membranes were washed, incubated with diluted HRP-conjugated
secondary antibodies (Amersham Biosciences), and developed by the
enhanced chemiluminescence (ECL) detection system (Amersham
Biosciences).
2.10. 2-D image analysis and MALDI-MS
2-D of prepared MCM and MALDI-MS analysis were performed as
reported previously, with some modiﬁcations [28]. In brief, 400 mg of
secreted protein were applied to a 13 cm immobilized nonlinear
gradient strip (pH 3–10) (Amersham Biosciences), and focused at
8000 Vwithin 3 h. Second-dimension separationwas performed using
12% polyacrylamide gels (chemicals from Serva and Bio-Rad). 2-D gels
were stained with colloidal Coomassie blue (Invitrogen) or silver
nitrate for 24 h, and destained with deionized water. ImageMaster™
software (Amersham Biosciences) was applied for image analysis of
2-D gels. Protein spots in control MCM and those displaying altered
secretion patterns in the presence of LPS or IFN-γ were subjected to
MALDI-MS for identiﬁcation.
For MALDI-MS analysis, protein spots in 2-D gels were excised,
destained with 50% acetonitrile in 0.1 M ammonium bicarbonate, and
dried in a Speedvac evaporator. Dried gel pieces were reswollen with
30 μl of 25 mM sodium bicarbonate, pH 8.8, containing 50 ng trypsin
(Promega, Madison) at 37 °C overnight. α-Cyano 4 hydroxycinnamic
acid (Bruker Daltonics) (20 mg) was dissolved in 1 ml acetone:
ethanol (1:2, v/v), and 0.5 μl matrix solution was mixed with an
equivalent volume of sample. The sample was analyzed using an
Ultraﬂex TOF/TOF system (Bruker Daltonics). Peptide masses were
matched with the theoretical peptide masses of proteins from all
species in the Mascot database.
2.11. Statistical analysis
Data are expressed as means±SEM, and analyzed for statistical
signiﬁcance using analysis of variance (ANOVA) followed by Scheffe's
test for multiple comparison. A p value of b0.05 was considered
signiﬁcant.
3. Results
3.1. Microglia conditioned culture medium (MCM) decreases glioma cell
viability and activated MCM is more potent in inducing glioma cell death
We investigated the effects of BV2 microglia conditioned culture
medium (MCM) on proliferation or survival of astrocytes and glioma.
Conditioned culture media prepared from primary cultured rat
microglia or murine BV2 cell line were incubated with rat primary
astrocytes or CRT-MG human astrocytic glioma cells. Cell viability was
measured with the MTT assay at 72 h. Transfer of MCM prepared from
BV2 or primary microglia markedly reduced the viability of CRT-MG
cells. In contrast, astrocytes were not signiﬁcantly inﬂuenced by MCM
(Fig. 1A). Rather, MCM consistently induced low-level proliferation of
astrocytes (Figs. 1A and C and 2F). We additionally examined cellstatus and morphological changes after MCM treatment (Fig. 1B).
Incubation of astrocytes or CRT-MG cells with MCM of BV2 and
primary cultured rat microglial cells for 72 h triggered a dramatic
decrease in glioma numbers and morphological changes into
elongated shape followed by detaching from plates but no signiﬁcant
changes of astrocytes in terms of both cell number and phenotype.
To determine the inﬂuence of MCM prepared from activated
microglia, BV2 cells were treatedwith thewell-characterized immune
stimulants bacterial lipopolysaccharide (LPS), thrombin, or IFN-γ
[22,23,29], followed by collection of MCM. MCM consistently exerted
cytotoxic effects on CRT-MG cells. Moreover, LPS-stimulated MCM of
BV2 or primary microglia had a more potent effect in a dose-
dependent manner (Fig. 1C and Suppl. Fig. 1). In comparison,
astrocytes were not inﬂuenced by MCM, and minimally affected by
activatedMCM. LPS, administered directly at equivalent doses, did not
affect cell viability or proliferation of CRT-MG or astrocytes. The
inﬂuences of residual LPS in activatedMCMwere tested. Co-treatment
with LPS (1, 5, or 10 ng/ml) and MCM did not signiﬁcantly change the
cytotoxic effects of MCM alone (Suppl. Fig. 2).
ActivatedMCMprepared fromLPS-, thrombin-, or IFN-γ-stimulated
BV2 cells exerted potent cytotoxic effects on CRT-MG survival to a
similar extent (data not shown). Next,we examined the effects ofMCM
and activated MCM on several other rat (C6) or human (U87-MG and
U373-MG) glioma cell lines. As expected, MCM induced cytotoxicity in
C6, U87-MG, and U373-MG cells and activated MCM (Fig. 1D) exerted
more signiﬁcant cytotoxicity, indicating that these effects on glioma
cells are general rather than cell type-speciﬁc.
3.2. MCM and activated MCM trigger apoptosis of glioma cells
Cells were then subjected to DAPI staining, which revealed
chromatin condensation, a hallmark of apoptosis. Incubation of CRT-
MG with MCM showed condensed nuclei, and incubation with
activated MCM gave rise to condensed nuclei with evidence of DNA
fragmentation (Fig. 2A). MCM and activated MCM prepared from rat
primary microglia also induced nuclei condensation and DNA
fragmentation in CRT-MG cells (data not shown). This apoptotic
characteristic was conﬁrmed by cell cycle analysis. Cells were treated
with propidium iodide and the percent of sub-G1 phase, characterized
as fragmented DNA, was determined by FACS analysis. Treatment of
MCM resulted in 9.54% of cells entering the sub-G1 phase, which is an
indicator of apoptosis, and this proportion increased to 22.72% for
cells treated with activated MCM (Fig. 2B). Moreover, PARP cleavage,
the ﬁnal stage marker of apoptosis, was observed at 24 h in BV2 cells
and rat primary microglia incubated with MCM or activated MCM
(Fig. 2C).
To further verify MCM-induced apoptotic death, we treated the
MCM-treated CRT-MG glioma cells with the general apoptosis
inhibitor zVAD-fmk and examined whether the apoptosis was
blocked. zVAD-fmk (1, 10, or 100 μM) was incubated with or without
MCM to treat glioma cells. Observing under a light microscope, MCM-
induced cell death was almost completely blocked by zVAD-fmk (Fig.
2D). While zVAD-fmk itself exerted dose-dependent cytotoxicity
(about 15% cell death at 10 μM), MCM-triggered apoptosis was
signiﬁcantly suppressed, as measured with the MTT assay (Fig. 2E).
However, zVAD-fmk alone had no signiﬁcant effects on astrocytes
and MCM-treated astrocytes (Fig. 2F). zVAD-fmk (10 μM) also
suppressed cytotoxicity induced by MCM of rat primary microglia
(Suppl. Fig. 3).
3.3. NO inﬂuences glioma cell death
3-Morpholinosydnonimine (SIN-1) is a potent exogenous donor of
peroxynitrite, a highly reactive molecule formed from NO in aqueous
solutions [30]. Treatment of astrocytes or the glioma subconﬂuent
monolayer with SIN-1 (0–1000 μM) for 72 h induced nitric oxide in a
Fig. 1. Induction of CRT-MG glioma cell death by MCM and MCM prepared from activated microglia. (A and B) Conditioned media of unstimulated BV2 (BV2-MCM) or rat primary
microglia (pMCM) were prepared and incubated with astrocytes (Ast) or CRT-MG glioma cells for 72 h. (A) Cell survival was determined using the MTT assay. (B) Cell status and
morphology were observed using phase-contrast light microscopy. (C) BV2 cells were left untreated or stimulated with 1, 5, or 10 ng/ml of LPS for 24 h. MCM prepared from control
and activated BV2 cells was incubated with astrocytes or CRT-MG cells. As a control, equivalent doses of LPS were added directly to astrocytes and CRT-MG cells. Cell viability was
measured at 72 h using the MTT assay. (D) BV2 cells were left untreated or stimulated with LPS (100 ng/ml), IFN-γ (IFN) (20 U/ml), or thrombin (Thr) (50 U/ml). BV2-MCM was
collected 24 h later, and incubated with C6 rat glioma and U87-MG and U373-MG human glioma cells for 72 h. Glioma cells treated directly with LPS (100 ng/ml), IFN-γ (20 U/ml), or
thrombin (50 U/ml) were used as control cultures. Cell viability was measured using the MTT assay. Bars represent means±SEM of three independent experiments. ⁎ represents
values signiﬁcantly decreased in BV2-MCM or pMCM, compared to control cultures. ⁎⁎ indicates values signiﬁcantly decreased byMCM, compared to control cultures. ⁎⁎⁎ represents
values that differ signiﬁcantly between activated MCM and MCM.
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that at these doses, SIN-1 does not signiﬁcantly affect the cell viability
of astrocytes (Fig. 3B, phenotypic data not shown). In contrast, SIN-1
mediated cytotoxic effects in CRT-MG glioma cells at concentrations
higher than 200 μM (Fig. 3B) in a dose-dependent manner. Next, the
effects of [NG-monomethyl-l-arginine(l-NMMA)], a NOS-speciﬁc
inhibitor, were examined (Fig. 3C). After BV2 cells were stimulated
with LPS with or without NMMA, MCM was prepared and applied to
CRT-MG cells. Speciﬁcally, only glioma cell death by activated MCM
was signiﬁcantly suppressed in the presence of NMMA. The data
clearly suggest that NO released by activated microglia plays a major
role in glioma cytotoxicity.
Not only do activated microglia exhibit increased production of
NO, they also produce increased levels of proinﬂammatory cytokines
and chemokines. It has been suggested that microglia represent the
ﬁrst line of CNS defense against brain tumors by virtue of the cytotoxic
potential of the proinﬂammatory cytokines, IL-1, IL-6, IL-10, TNF-α,
and/or TGF-β [5]. In our supplementary experiments, we examined
the effects of proinﬂammatory cytokines on glioma cell fate and found
that treatment with cytokines, such as IL-1β, TNF-α, or IL-6, did not
affect the viability of CRT-MG cells (Suppl. Fig. 4A). Combinedtreatment with IL-1β, TNF-α, and IL-6 induced a modest decrease in
cell viability, but signiﬁcantly potentiated SIN-1-induced (100 and
200 μM) cytotoxicity (Suppl. Fig. 4B).
3.4. 2-D mapping to identify proteins secreted from BV2 for altered
secretion patterns in the presence of LPS or IFN-γ and validation of 2-D
mapping results by Western blotting
In order to identify proteins in MCM, microglial proteins secreted
from non-treated control MCM and that stimulated by LPS or IFN-γ
were separated on the basis of their own pI and molecular weight
(MW) on a 2-D gel. MCM was collected, concentrated, precipitated
with TCA, and subjected to 2-D gel electrophoresis (0.4 mg/gel). After
colloidal Coomassie blue staining, over 200 protein spots were
detectable on each 2-D gel. Protein spots that displayed altered
secretion patterns in the presence of LPS and IFN-γ were selected
using image analysis software, and subjected to MALDI-MS analysis.
Some spots could not be characterized with MALDI-TOF due to
insufﬁciencies or overlap. In total, 54 protein spots were identiﬁed
(Table 1). Swiss-Prot numbers of proteins displaying increased or
decreased secretion following treatment with LPS and IFN-γ are
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Fig. 3. The inﬂuence of SIN or NMMA on glioma cell death. Primary astrocytes or CRT-MG glioma cells were treated with different concentrations of SIN-1 (0, 100, 200, 400, 500, or
1000 μM) for 72 h. (A) Nitric oxide production was evaluated bymeasuring nitrite in the culturemedium. (B) Cell survival was determinedwith theMTT assay. (C) BV2 cells were left
untreated or pretreated with increasing concentrations of NMMA for 1 h before application of LPS (100 ng/ml). Cell-free conditioned culture medium was collected 24 h later, and
incubatedwith the CRT-MG human glioma cell line for 72 h. As a control, equivalent doses of LPS and NMMAwere added directly to CRT-MG cells. Survival rates of primary astrocytes
and CRT-MG glioma cells were determined with the MTT assay. Bars represent means±SEM of three independent experiments. ⁎ Indicates values signiﬁcantly different from
untreated control cultures. ⁎⁎ Indicates values signiﬁcantly increased compared to control cultures incubated with activated MCM.
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analysis-based selection of apolipoprotein E (ApoE) (AAA37251) and
cathepsin L (P06797) precursors as proteins displaying down-
regulated secretion in the presence of LPS and IFN-γ. The majority of
secreted proteins were not altered in the presence of LPS and IFN-γ
(Fig. 4A). Among these proteins, 33 were identiﬁed to indicate
landmark proteins and normalize the level of protein secretion
(Table 1). The differential expression of a subset of identiﬁed proteins,
such as ApoE, cathepsin L, and other cathepsin family proteases, was
validated by Western blot analysis. Prior to Western blotting, silver
staining of a SDS–PAGE gel was performed to detect protein patterns
and conﬁrm equivalent amounts of secreted protein (Suppl. Fig. 5). 2-DFig. 2. Induction of glioma cell apoptosis by MCM and activated MCM. (A–C) BV2 microglia c
24 h. Cell-free conditioned culture medium {MCM for untreated and MCM(L) for LPS stimul
CRT-MG cells treated with LPS (100 ng/ml) were employed as control cultures. (A) Cell st
microscope (upper panel). Cells were stained with DAPI and analyzed by ﬂuorescence micr
DNA with propidium iodide, followed by FACS analysis at 24 h. The sub-G1 peak, marked as
and GAPDH were detected on a Western blot. Data in (C) are representative of three separ
indicated concentrations of zVAD-fmk for 72 h. The morphology of CRT-MG glioma cells was
experiments. (E and F) CRT-MG glioma cells (E) or rat astrocyte cells (F) were treated with or
were determined with theMTT assay. Data aremeans±SEM of three independent experimenWestern blotting for ApoE conﬁrmed the presence of several subtypes
or modiﬁed forms of ApoE proteins in MCM. Moreover, their levels
were reduced in MCM preparations from LPS- or IFN-γ-stimulated
microglia (Fig. 4C). In contrast, the ApoE mRNA level was not affected
by LPS or IFN-γ (Suppl. Fig. 6). ApoE and cathepsin L, A, B, andD protein
levels were evaluated by Western blotting. Decreased secretion was
observed in the presence of LPS and IFN-γ (Fig. 4D). Notably, these
proteins were not detected in whole cell lysates, suggesting that they
are truly secretory proteins. The decrease in the cathepsin L, B, and D
proteins level as a result of LPS and IFN-γ treatment was additionally
conﬁrmed in primary microglial cells (Suppl. Fig. 7). HSP60 was
strongly detected in whole cell lysates, compared to the low levelells or rat primary microglia were left untreated or stimulated with LPS (100 ng/ml) for
ated} was collected, and incubated with CRT-MG human glioma cells for a further 24 h.
atus and morphological changes in CRT-MG glioma cells were observed under a light
oscopy (lower panel). (B) Cell cycle analysis was performed after labeling intracellular
M1, indicates fragmented DNA. (C) Total cell lysates were prepared and PARP cleavage
ate experiments. (D) CRT-MG glioma cells were treated with or without MCM and the
observed under a light microscope. Shown data are representative of three independent
without MCM and the indicated concentrations of zVAD-fmk for 72 h. Cell survival rates
ts. ⁎ Indicates values signiﬁcantly increased compared to cultures incubated withMCM.
Table 1
Identiﬁcation of secretory proteins obtained from BV2.





Landmarks Q9ES94 Cathepsin Z 34,837 6.13 13 33
JC1224 Nucleobindin precursor 52,965 4.99 20 41
A45935 DnaK-type molecular chaperone hsc70 71,021 5.37 41 55
S25197 Transitional endoplasmic reticulum ATPase 89,936 5.14 22 38
P58252 Elongation factor 2 (EF-2) 96,091 6.42 37 41
Q9CZW9 5-Aminoimidazole-4-carboxamide ribonucleotide formyltransferase 62,351 6.65 23 33
Q99LF6 Protein disulﬁde isomerase associated 3 57,099 5.88 27 60
BAC35834 Unnamed protein product 57,783 5.97 24 60
P05064 Fructose-bisphosphate aldolase A 39,787 8.31 19 71
S74227 Cathepsin K (EC 3.4.22.-) precursor 37,100 8.62 16 36
P63260 Actin, cytoplasmic 2 (Gamma-actin) 42,108 5.31 23 60
S06763 Calreticulin precursor 48,136 4.33 20 50
Q8C530 Rab GDP dissociation inhibitor beta (Rab GDI beta) 5.93 28 57
P97324 Glucose-6-phosphate 1-dehydrogenase 2 (EC 1.1.1.49) (G6PD). 59,550 6.07 35 60
P17182 Alpha-enolase (EC 4.2.1.11) 47,322 6.36 27 62
Q9CXW3 Calcyclin-binding protein (CacyBP) (Siah-interacting protein) 26,608 7.63 14 48
P09411 Phosphoglycerate kinase 1 (EC 2.7.2.3) 44,700 7.52 18 51
Q9DBJ1 Phosphoglycerate mutase 1 (EC 5.4.2.1) 28,700 6.75 17 47
Q99LB4 Capg protein 39,030 6.47 13 45
P52480 Pyruvate kinase isozyme M2 (EC 2.7.1.40) 58,289 7.42 25 45
Q8BQV9 5-Aminoimidazole-4-carboxamide ribonucleotide formyltransferase 37,854 5.65 19 56
P68143 Actin, cytoplasmic 1 (beta-actin) 42,000 5.29 28 70
Q8BK18 Aspartyl-tRNA synthetase (EC 6.1.1.12) 57,567 6.16 16 38
Q9JHU9 Myo-inositol 1-phosphate synthase A1 (EC 5.5.1.4) 61,520 5.99 12 28
P18242 Cathepsin D precursor 45,381 6.71 12 36
P08709 Peroxiredoxin-6 24,938 5.72 9 46
Down-regulated proteins in LPS-
or IFN-γ-treated BV2
BAC36723 Unnamed protein product 40,063 9.36 14 44
AAA37251 Apolipoprotein E precursor 35,901 5.56 24 49
AAL34533 Transferrin 78,794 6.92 29 36
P06797 Cathepsin L precursor 38,075 6.37 25 75
AAD54617 Lysyl hydroxylase 1 84,113 6.08 31 43
Q8CFJ4 Ariadne ubiquitin-conjugating enzyme E2 binding protein homolog 1 54,382 7.65 11 24
Up-regulated proteins in
IFN-γ-treated BV2
Q8C2C7 Heat shock protein, 60 kDa 60,956 5.67 23 51
C25437 Tubulin beta-3 chain 50,255 4.79 27 48
Q9D2D1 Protective protein for beta-galactosidase 54,423 5.56 24 28
P09103 Protein disulﬁde isomerase precursor 57,422 4.79 28 54
BAB23644 Unnamed protein product 53,376 4.99 28 50
S43061 T-complex-type molecular chaperone Ccte 60,042 5.72 40 61
Q923D2 Flavin reductase (FR) (NADPH-dependent diaphorase) 22,297 6.49 12 74
A48513 Macrophage 23K stress-induced protein 22,390 8.26 21 52
BAB23595 Unnamed protein product 22,379 5.68 10 51
I57010 Purine-nucleoside phosphorylase (EC 2.4.2.1) 32,541 5.78 21 55
I58195 Y box-binding protein 1 35,723 9.98 13 47
P11499 HSP 90-beta (Tumor-speciﬁc transplantation 84 kDa antigen) (TSTA) 83,484 4.97 31 43
S28182 Lamin A 74,482 6.41 16 32
Q922R8 Protein disulﬁde isomerase A6 precursor 48,100 5.00 17 31
Up-regulated proteins in
LPS-treated BV2
AAF14001 Scavenger receptor type A SR-A 50,707 6.48 22 39
Q99KQ4 Nicotinamide phosphoribosyltransferase 55,698 6.69 21 57
AAH57565 Tyki protein 47,301 5.98 19 36
Q9JII6 Alcohol dehydrogenase [NADP+] (EC 1.1.1.2) 36,661 6.87 17 42
AK049817 Purine-nucleoside phosphorylase 32,527 5.78 15 54
Q9CWE7 Triosephosphate isomerase 27,109 6.90 10 35
AAH89335 Vimentin 53,712 5.06 24 60
C25437 Tubulin beta-3 chain 50,255 4.79 27 48
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HSP60 immunoblotting revealed equivalent amounts of secretory and
whole cell lysate proteins (Fig. 4D).
3.5. Protease inhibitors, AEBSF, E-64, and LLnL, suppress microglia
activation, and E-64 partially reverses MCM-induced cell death
We examined the effects of proteases on microglia behavior, and
consequently, glioma cell death. The effects of a general serine
protease inhibitor {4-(2-aminoethyl)benzenesulfonylﬂuoride
(AEBSF)}, a cysteine protease inhibitor [31], a cathepsin D inhibitor
(pepstatin A), and a proteasome inhibitor {N-acetyl-L-leucyl-L-leucyl-
L-norleucinal (LLnL)} on both microglia activation and MCM-induced
glioma cell death were evaluated. Pretreatment of BV2 cells withAEBSF, E-64, or LLnL led to strong inhibition of mRNA induction of
proinﬂammatory molecules, such as COX-2, IL-1β, TNF-α, and IL-6, as
well as iNOS (Fig. 5A). Consistent with this, AEBSF, E-64, and LLnL
suppressed iNOS protein expression in BV2 cells (Fig. 5B). The effects
of AEBSF were further conﬁrmed by suppression of NO release in a
dose-dependent manner (Fig. 5C). Similar inhibitory effects on NO
release and activation-induced cell death were observed with E-64
and LLnL (data not shown).
Next,we examinedwhetherAEBSF, E-64, or LLnL regulate gliomacell
deathmediated bymicrogliaMCM. The serineprotease inhibitor, AEBSF,
had little effect onMCM-induced cell death (Fig. 5D). Additionally, LLnL
exerted no signiﬁcant inﬂuence (data not shown). However, treatment
with E64, a general cysteine protease inhibitor, which also acts on
lysosomal cysteine cathepsins [32], resulted in suppression of MCM-
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Fig. 4. Reference 2-D maps of MCM prepared from control and LPS- or IFN-γ-activated mouse BV2 microglia and validation of proteins displaying altered secretion patterns in the
presence of LPS, or IFN-γ. Images were scanned at a resolution of 300 DPI. Proteins (250 μg) were separated on a nonlinear pH 3–10 IPG strip, followed by 10% SDS–PAGE.
Approximately 400 modiﬁed Coomassie-stained protein spots were detected with the ImageMaster™ software program on each gel. (A) Typical patterns of 2-D gels of secretory
proteins. Up- or down-regulated proteins in MCM of BV2 cells treated with LPS or IFN-γwere selected with ImageMaster™. Proteins were excised from the main gel and digested
with trypsin, and peptides were analyzed by MALDI-MS. Proteins were identiﬁed based on peptide mass. Swiss-Prot accession numbers of normal and up- and down-regulated
proteins were labeled in black, red, and blue, respectively. (B) Enlarged partial images of gels containing apolipoprotein E (AAA37251) and cathepsin L (P06797) precursor protein
spots. Enlarged 2- and 3-dimensional images disclose down-regulation of these two proteins in MCM of LPS- or IFN-γ-treated BV2. (C) BV2 cells were left untreated (cont) or
stimulated with 10 ng/ml of LPS or 20 U/ml IFN-γ for 24 h. Coomassie blue staining (coom.) andWestern blotting (WB) of apolipoprotein E proteins after 2-D gel electrophoresis of
BV2 secretory proteins. (D) Western blotting of secretory proteins (MCM) and whole cell lysates (WCL). BV2 cells were left untreated (cont) or stimulated with 10 ng/ml LPS or
20 U/ml IFN-γ for 24 h. An aliquot of protein (20 μg per lane) was separated in 10% SDS–PAGE and subjected to Western blotting for apolipoprotein E (ApoE) and cathepsin (Cat)
protease family (A, B, D, and L) proteins. Ponceau S (Pon S)-stained protein blots reveal equal protein loading per lane. Shown data are representative of at least three separate
experiments.
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hampered since E-64 itself displayed some toxicity, particularly at
higher concentrations (N15% cell death at doses higher than 5 μM).
Nevertheless, E-64 protected glioma cells from MCM-induced death.
3.6. The cathepsin B inhibitor, CA-074me, suppresses MCM-induced
glioma cell death
We next addressed whether microglia-secreted cathepsins are
essential in stimulating cytotoxicity in glioma cells. Neither micro-
glial activation nor MCM-mediated cell death was inﬂuenced by
cathepsin B, L, and S speciﬁc inhibitors, Z-FG-NHO-BzME, and Z-FG-
NHO-Bz (data not shown). Moreover, immunodepletion of cathep-
sins with speciﬁc antibodies for cathepsin A, B, D, L, and K did not
abolish the cytotoxic effects of MCM on CRT-MG glioma cells (data
not shown). Strikingly, inhibition of the enzymatic activity of
cathepsin B by CA-074me to MCM demonstrated inhibition of
glioma cell death (Fig. 6A and B). CA-074me did not inﬂuence
astrocyte either alone or in combination with MCM (Fig. 6C).Importantly, general cysteine protease inhibitor, E-64, together with
CA-074me displayed an additive effect on protection against MCM-
induced glioma cell death (data not shown), indicating that other
cysteine proteinases also can be involved in cytotoxicity. Direct
treatment of CRT-MG with cathepsin B caused a decrease in cell
survival (by ∼20%) (Fig. 6D). These results strongly suggest that
cathepsin B is an important mediator of MCM-induced glioma cell
death.
4. Discussion
Since microglia produce and secrete various molecules in both the
resting and activated states, microglia-mediated responses to brain
tumors may be broadly inﬂuenced by secreted soluble factors. The
microglial soluble factor(s) involved in glioma proliferation or death
remain to be identiﬁed. In this report, we show that substance(s)
released by microglia induce apoptosis of astrocytic glioma cells.
Signiﬁcantly, the cytotoxic effects of MCM were speciﬁc for astrocytic
glioma cells, since primary cultured astrocyte survival was not
Fig. 5. Effects of various protease inhibitors on microglia activation and MCM-induced glioma cell death. BV2 microglia cells were left untreated or stimulated with LPS (100 ng/ml)
in the presence of AEBSF (100 μM for A and B), E-64 (10 μM), LLnL (2.5 μM), and pepstatin A (pepst) (10 μM) for 24 h. (A) Total RNA was extracted and mRNA levels were measured
by RT-PCR using speciﬁc primers. (B) Western blotting of total cell lysates (20 μg of protein sample per lane) subjected to 10% SDS–PAGE. (C) BV2 cells were pretreated with varying
concentrations of AEBSF, and nitrite levels were determined. (D) CRT-MG glioma cells were incubated with MCM prepared from BV2with or without the indicated concentrations of
AEBSF or E-64. At 72 h, cell status and morphological changes in CRT-MG glioma cells were observed under a light microscope. Data in (A), (B), and (D) are representative of four
independent experiments. Data presented in (C) are means±SEM of three independent experiments. The asterisk represents signiﬁcant reduction compare to cells stimulated with
LPS alone.
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Fig. 6. Effects of CA-074me onMCM-induced glioma cell death and inﬂuence of cathepsin B on glioma cell proliferation. (A) MCMwith or without the indicated concentrations of CA-
074me was incubated with CRT-MG glioma cells for 72 h. The morphology of CRT-MG glioma cells was observed under a light microscope. (B) Survival rates of CRT-MG glioma cells
and (C) primary astrocyte cells were determinedwith theMTT assay. (D) The CRT-MG glioma cell line was directly treated with exogenous cathepsin B for 72 h. Cell morphology was
observed under a light microscope (left panel) and cell survival rates were determined with the MTT assay (right panel). Data in (A) and (D) are representative of three independent
experiments. Data presented in (B) and (C) aremeans±SEM of three independent experiments. ⁎ Indicates values signiﬁcantly increased compared to cultures incubatedwithMCM.
⁎⁎ Indicates values signiﬁcantly different from untreated control cultures.
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astrocytes (data not shown). This selective cytotoxic effect was
enhanced upon microglial activation.
The viability of glioma cells was remarkably decreased in the
presence of SIN-1 at concentrations of 400–1000 μM, which usually
releases about 20–40 μM nitrite into culture medium at 72 h. In
contrast, astrocytes were resistant to SIN-1, even at 1000 μM. The data
suggest that activated microglia selectively induce glioma cell
apoptosis by activating iNOS and subsequent release of NO.
Furthermore, we also found that combined treatment with IL-1β,
TNF-α, and IL-6 signiﬁcantly potentiated SIN-1-induced cytotoxicity.Thus, our report provides new information, demonstrating that
microglial-secreted NO acts in concert with proinﬂammatory cyto-
kines to play an important role in regulating tumor growth.
NO effect was insufﬁcient to explain glioma cell death by MCM.
MCM induced signiﬁcant cell death, despite the presence of very low
levels of NO. Furthermore, inclusion of NOS inhibitors into microglia
culture led to signiﬁcant suppression of glioma cell deathmediated by
activated MCM, but not by MCM. Thus, it is likely that NO in the
activated MCM is the principal cytotoxic mediator of glioma, while
cathepsin B released bymicroglia in the resting state may be critical in
the induction of glioma cytotoxicity.
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sources in the culture medium elicits apoptosis of glioma cells. To
eliminate this possibility, we added pyruvate (2 mM) to the culture
medium as an energy source, which did not affect glioma apoptosis
(data not shown). In addition, conditioned culture medium prepared
similarly from other cells (rat2 mouse ﬁbroblasts or A549 lung
adenocarcinoma cells) elicited no signiﬁcant effects on glioma cell
survival or proliferation (data not shown). Furthermore, conditioned
media from rat2 mouse ﬁbroblasts or A549 lung adenocarcinoma cells
stimulated with LPS or IFN-γ did not induce any inﬂuences on glioma
cell survival/proliferation (data not shown). Nonetheless, there is no
evidence to rule out the possibility of depletion of critical factor(s)
required for glioma survival in MCM.
To identify the proteins secreted by microglia and compare their
expression patterns in the unstimulated and stimulated states, we
established 2-D maps of BV2 microglia secretory proteins obtained
from either control MCM orMCM stimulated by LPS or IFN-γ. Notably,
apolipoprotein E (ApoE) and cathepsin proteases displayed the most
marked alterations in the presence of LPS and IFN-γ. Our ﬁnding that
ApoE is down-regulated in BV2 MCM treated with LPS and IFN-γ is
consistent with previous reports [33,34]. Moreover, the low level of
endogenous ApoE in non-treated and LPS- and IFN-γ-treated cells
suggests that either secretion or protein expression of ApoE is
regulated. Since the mRNA level of ApoE was not changed by LPS or
IFN-γ, we hypothesize that the secretion phase or protein stability is
regulated. Immunodepletion of ApoE using speciﬁc antibodies did not
inﬂuence MCM-mediated apoptosis of glioma (data not shown). In
addition, exogenous ApoE4 did not induce phenotypic or cytotoxic
effects on glioma cells (data not shown), ruling out its direct
involvement in glioma cell survival. While the effects of other
isoforms of ApoE (ApoE2 and ApoE3) remain to be established,
current data suggest that the protein does not have a critical function
in microglia-mediated cytotoxicity of glioma cells.
In our experiments, secretion of several lysosomal cathepsin
proteases (A, B, D, and L) was suppressed by LPS or IFN-γ. In contrast
to our ﬁndings, up-regulated extracellular accumulation of cathepsin
L has been reported in IFN-γ-treated macrophages and LPS-activated
dendritic cells [35]. In addition, treatment of human U-937monocytes
and macrophages with IFN-γ leads to an increase in the activity and
content of cathepsins B and L [35,36]. These inconsistent results may
reﬂect the characteristics of microglia response in neuroinﬂammation
processes and various neuronal diseases. Up-regulated extracellular
accumulation of cathepsin D has been also reported in LPS/IFN-γ-
treated BV2 cells [37]. While the reason for the discrepancy in
response between LPS or IFN-γ and LPS plus IFN-γ for cathepsin D
release remains to be elucidated, one possibility includes that
combinatory signals from LPS and IFN-γ are required for increased
expression of cathepsin D. Among the cathepsin proteins, the
importance of cathepsin B in inﬂammation-related cytotoxicity has
been extensively examined. E-64 and CA-074me [32,38], inhibitors for
cathepsin B, signiﬁcantly suppressed glioma apoptosis. In view of
these results, we propose that cathepsin B is a critical factor in MCM-
mediated glioma death. The puriﬁed cathepsin B induced signiﬁcant
but relatively mild cytotoxic effect on glioma (∼20% reduction in cell
viability). This may be due to the relatively weak biological effect of
puriﬁed cathepsin B compared to endogenous proteins or the
potential presence of a critical regulator or cofactor of cathepsin B in
MCM. Accumulating knowledge on proteolytic events and subsequent
effects in brain inﬂammation and cell death mediated by microglial
proteaseswill not only contribute to a better understanding of the role
of microglial-secreted proteins in the CNS but also aid in the
development of protease inhibitors as novel neuroprotective or
neuro-immunoregulatory agents. Given the dynamic regulation of
microglia-secreted proteins, characterization of the functions of other
cathepsin proteins (A, D, K, L, and Z) in brain physiology and
pathology is essential. It has been shown that microglial producedMMP-3 or -9 are involved in microglial activation [39,40]. While the
roles of MMPs in glioma invasion are described in many reports, few
studies focused on apoptotic effects of MMPs to glioma cells. Our
proteomic data did not show any evidences for (changed) expression
of MMPs in BV2 conditioned medium.
To date, 2-D-based proteome mapping has been limited to the
detection of large proteins or relatively high concentrations of
proteins. Thus, low abundance proteins have undoubtedly been
overlooked due to the inadequate sensitivity of Coomassie blue
staining. Future laboratory analyses will employ ﬂuorescent stains or
isotope labeling, which should allow the efﬁcient analysis of less
abundant proteins.
In conclusion, our results support the idea that microglia play an
active role in the regulation of tumor cell death by local secretion of
NO and cathepsin B. It is currently unclear how exogenous cathepsin B
initiates or propagates proapoptotic signals. One possibility includes
that cathepsin B could nonspeciﬁcally degrade important cell surface
proteins, thereby causing the cell to initiate apoptosis. Alternatively,
cathepsin B could cleave extracellular matrix proteins, which are
important for cell survival, thereby causing apoptosis. We expect that
future studies aimed at identifying the downstream targets of
cathepsin B effects will contribute to the understanding of microglial
produced proteases in pathogenesis of brain tumor. Because micro-
glial secretion of these molecules is dynamically regulated by
stimulation with LPS or IFN-γ, the modulation of microglial activation
may contribute to the control of brain neoplasms.
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